1 BTC
=
- USD
GoodRx Holdings, Inc. Class A Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About GoodRx Holdings, Inc. Class A Common Stock
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Market Statistics
Trading Metrics
How to Buy GDRX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy GDRX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesGoodRx faces revenue stagnation with Q1 2026 sales declining 4.4% year-over-year to $194 million, though its Pharma Direct business showed encouraging 82% growth. Meanwhile, Hims & Hers Health demonstrates strong momentum with 59% year-over-year revenue growth in Q4 2025 and 13% subscriber growth, capitalizing on rising healthcare costs and limited access to primary care physicians.
GoodRx Holdings shares rose 2.69% as the company expanded access to Novo Nordisk's Wegovy HD, a higher-dose GLP-1 treatment for self-pay patients priced at $399 per month. The expansion reflects growing demand for GLP-1 obesity treatments and GoodRx's efforts to simplify medication access. The company also recently expanded access to Eli Lilly's oral GLP-1 medication Foundayo and Zepbound.
Amazon has entered the GLP-1 weight loss drug market by offering Novo Nordisk's Wegovy pill through its pharmacy service at competitive prices ($25-$149 per month). This move could significantly impact competitors like Hims & Hers, WW International, and GoodRx, as Amazon leverages its 200 million Prime members and e-commerce platform. While the pill form is expected to drive overall GLP-1 adoption, Amazon's scale and reach pose a competitive threat to specialized GLP-1 retailers.
Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.
